Resource Library

Zambia Ending AIDS Campaign Materials

JSI's USAID DISCOVER-Health Project contributes towards HIV epidemic control in Zambia and has produced a number of PrEP campaign materials. See below! Tools PrEP Your Client for Protection in 5 Easy Steps Be Ready with PrEP Fact Sheet Be Ready with PrEP Frequently Asked Questions Zambia Ending AIDS Posters Videos Introduction to Zambia Ending AIDS…

Demand Creation/Marketing, Service Delivery

Plan 4 PrEP: Step 5: Facility Readiness Assessment

Service Delivery

Health Care Providers as Agents of Change: Integrating PrEP with other sexual and reproductive health services for adolescent girls and young women

Providing integrated HIV PrEP and sexual reproductive health (SRH) care is difficult for many healthcare providers. They face many barriers. Successul integration will require interation and adaptation. O'Malley et al. investigate the structural and motivational barriers that healthcare providers face in providing integrated care to adolescent girls and young women (AGYW).

Research, Service Delivery

A community-based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa

This study explores the feasibility and acceptability of providing PrEP to adolescent girls and young women via a community-based mobile health clinic known as the Tutu Teen Truck in Cape Town, South Africa

Research, Service Delivery

Sexually Transmitted Infections Among African Women: An opportunity for combination sexually transmitted infection/HIV prevention

The global epidemic of Sexually Transmitted Infections (STIs) in women demands new prevention approaches. This article outlines new strategies which are emerging that offer opportunities for research and program delivery of combination STI/HIV prevention .

Research

Project Hope Namibia PrEP Communication Toolkit

Duplicated resource, same as above

Demand Creation/Marketing

Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa

This study compares the effectiveness and cost-effectiveness of providing antiretroviral therapy vs PrEP in South Africa

Financing & Costing

Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa

This study estimates the cost-effectiveness of daily oral PrEP, with a protective effect against the herpes simplex virus as well as HIV, among HIV serodifferent couples in South Africa

Financing & Costing

FDA approves first drug for reducing the risk of sexually acquired HIV infection

This article from July 16, 2012 announces the U.S. Food and Drug Administration's approval of Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners.

Normative Guidance/Policies

From Proof-of-Concept to Prevention Phenomenon in Five Years

This timeline, first appearing in AVAC Report 2014/15: HIV Prevention on the Line, shows PrEP going from proof-of-concept to prevention phenomenon in five years and can be used to anticipate and speed action on the next generation of ARV-based prevention options.

Research